Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

Exclusion Criteria

• •Subject is known to be HIV positive or has HIV antibodies
• •Has clinically significant history or presence of illness, medical condition, or laboratory abnormality
• •Is Hepatitis positive
• •Subject with renal impairment has not been on a stable dose of concomitant medications for at least 4 weeks prior to start of study and/or dose changes are likely during the study
• •History of substance abuse within 6 months prior to screening
• •Has clinically significant history or presence of psychiatric illness, malignancy, or immunodeficiency syndrome
• •Has abnormal liver function tests (ALT, AST, and/or bilirubin)
• •Has had a blood transfusion or donated/lost more than 450ml of blood within 56 days of study drug administration or has donated plasma within 7 days prior to study drug administration